The webinar is the second in a series of webinars supported by an unrestricted educational grant from Pfizer, Inc. A team of specialized physician experts designed this webinar to provide education on the complexities of the use of echocardiography in the diagnosis of cardiac amyloidosis, including the complementary role of echocardiography and technetium labeled pyrophosphate nuclear cardiac scintigraphy (PYP). Cardiac amyloidosis is no longer a rare and untreatable disease. Recognition of the variation in echocardiographic findings and the proper use of PYP in non-invasive diagnosis is crucial to promote early diagnosis and improved outcomes. 

Speakers: Martha Grogan, MD and Rodney Falk, MD

Moderators: Milind Desai, MD, and Allan Klein, MD, FASE

CME/MOC Information: 1.0 AMA PRA Category 1 Credits^TM

Release Date: December 10, 2020

Expiration Date (Enduring Version): December 10, 2023 - CME/MOC must be claimed by this date.

PLEASE NOTE: Users who attended the live version of this webinar cannot also claim CME credit for the On-Demand Version. CME credit can only be claimed one time. 

The webinar is the second in a series of webinars supported by an unrestricted educational grant from Pfizer, Inc. 

This webinar will focus on the challenges of echocardiography in the diagnosis of cardiac amyloid, including patients with atypical patterns of amyloid deposition, and provide education on the complexities of the use of echocardiography in the diagnosis of cardiac amyloidosis, including the complimentary role of echocardiography and technetium labelled pyrophosphate nuclear cardiac scintigraphy (PYP). Cardiac amyloidosis is no longer a rare and untreatable disease. Recognition of the variation in echocardiographic findings and the proper use of PYP in non-invasive diagnosis is crucial to promote early diagnosis and improved outcomes. Interactive case-based sessions will highlight unusual and important echocardiographic findings in cardiac amyloid. The role of echocardiography in the diagnosis of cardiac amyloidosis using PYP scanning will be outlined. Drs. Grogan and Falk will be presenting with Drs. Klein and Desai serving as moderators. The webinar is structured to promote attendee participation with ample time allotted for questions and discussion.

Target Audience: This activity is designed for all cardiovascular sonographers and physicians with a primary interest and knowledge base in the field of cardiovascular imaging.

Learning Objectives:

1. Understand the challenges of identifying patients with cardiac amyloidosis, especially those with atypical findings.
2. Recognize the role of echocardiography in assessing prognosis in cardiac amyloid
3. Summarize the appropriate use of PYP in the diagnosis of cardiac amyloid, including the complimentary role of echocardiography in non-invasive diagnosis.

Accreditation Statement:

The American Society of Echocardiography is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Echocardiography designates this article for a maximum of 1 hour of AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1 MOC point in the American Board of Internal Medicine’s Maintenance of Certification (MOC) program.

ARDMS, CCI, Sonography Canada recognize ASE’s certificates and have agreed to honor the credit hours toward their registry requirements for sonographers.

Disclosures: 

According to ACCME policy, ASE implemented mechanisms to resolve all conflicts of interest prior to the planning and implementation of this activity.

The following moderators/speakers reported no actual or potential conflicts of interest in relation to this activity:

• Martha Grogan, MD
• Rodney Falk, MD

The following moderators/speakers reported relationships with one or more commercial interests:

• Milind Desai, MD - Myokardia (Research Grant)
• Allan Klein, MD, FASE – Pfizer (Consultant, Advisor)

The following CME reviewers and ASE Staff reported no actual or potential conflicts of interest in relation to this document: 

• Kathryn Lyons, ASE Healthcare Education Manager
• Bindu Chebrolu, MD, FASE
• Rita France, RDCS, RDMS, RT, FASE

• Contact:
  ASE Learning Hub